Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure

BACKGROUND: Nivolumab and regorafenib are approved second-line therapies for patients with hepatocellular carcinoma (HCC) after sorafenib failure. This study compared the effectiveness of nivolumab and regorafenib following sorafenib. METHODS: We retrospectively enrolled HCC patients who had undergo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Yuan-Hung, Yen, Yi-Hao, Chen, Yen-Yang, Kee, Kwong-Ming, Hung, Chao-Hung, Lu, Sheng-Nan, Hu, Tsung-Hui, Chen, Chien-Hung, Wang, Jing-Houng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201513/
https://www.ncbi.nlm.nih.gov/pubmed/34136408
http://dx.doi.org/10.3389/fonc.2021.683341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201513/
https://www.ncbi.nlm.nih.gov/pubmed/34136408
http://dx.doi.org/10.3389/fonc.2021.683341

Ejemplares similares